Why neighbours, not doctors, may be the key to cervical cancer prevention
While well-meaning, these tactics assume one key thing: that women are free to act on this information.The reality, as our study shows, is far more complex.Working across four Indian states, we found that two significant barriers stand in the way of CCS adoption: lack of awareness and disempowering sociocultural norms.Many women simply do not know what cervical cancer is or why they should get screened. More troubling, even when aware, fear, stigma, and dependence on male family members often stop women from seeking help.But there's hope, and it doesn't require expensive technology or a new infrastructure. Instead, it calls for rethinking who we empower to speak.DOCTORS VS PEERS: WHO DO WOMAN LISTEN TO?We ran large-scale field experiments comparing different messengers and messaging styles. Unsurprisingly, doctors were trusted and credible.When doctors delivered factual information about cervical cancer, its risks, symptoms, and treatments, women responded more favourably than they did to impersonal infographics.However, the real breakthrough came when the message was delivered by a peer, another woman from the same community, using a tone of empowerment rather than fear.When local women shared stories that normalised CCS, addressed common taboos, and encouraged others to take control of their health, the impact was transformative.The study showed that peer-delivered empowering messages were the right fit to persuade, leading to a 36.5% increase in screening adoption compared to standard methods.That's 21 million additional Indian women potentially getting screened, an enormous win for public health.EMPOWERMENT OVER FEARWhy does this work? Because women listen to women they relate to.When a neighbor shares that she went for a screening and is now encouraging others to do the same, it's not just a health message; it's social permission. It breaks the silence, eases fears, and creates a ripple effect of trust.This doesn't mean doctors aren't important. Their involvement still significantly boosts perceived value and willingness to pay for services.advertisementBut when it comes to changing behaviour, peers are often better placed to overcome stigma and cultural resistance, especially when they deliver messages that empower rather than scare.WHAT INDIA MUST DO NEXTThis insight has powerful implications for public health strategy. Here's what India can do:Rethink public health campaigns: Replace faceless posters and expert-heavy materials with real women from the community telling their stories in their own words.Train peer educators: Equip local health workers, ASHAs, and community leaders not just with facts but with tools to talk about screening in ways that resonate with women's daily lives and concerns. The tools do not have to be expensive. In our research, we used simple WhatsApp videos of messages from a female doctor and a female peer.Empower women to empower each other: Normalize conversations about reproductive health in women's self-help groups, anganwadi centers, and everyday settings like community kitchens or village meetings.Involve civil society: NGOs that already have deep community ties can be pivotal in scaling peer-led interventions. Camp based screenings by NGOs with clear referral pathways can be particularly effective.This isn't just about saving lives. It's about reclaiming agency for millions of Indian women. It's about shifting the healthcare narrative from 'you should do this' to 'let's do this together.'advertisementThe fight against cervical cancer won't be won in labs, clinics or lecture halls, it will be won in kitchens, community halls, and farm fields.By recognising the power of peer influence and contextualising our health messages to women's lived experiences, India has the chance to move from awareness to action, and from silence to survival.- Ends
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
an hour ago
- News18
Hyderabad Pharma Firm To Make Drug For Hard-To-Treat Bladder Cancer After Local Trials Waiver
For Indian patients battling aggressive bladder cancer driven by specific gene changes, a vital treatment may soon be available. Citing an 'unmet medical need" India's top drug advisory panel has approved a pharmaceutical firm's request to make and sell erdafitinib tablets in India by skipping a local third-phase trial but needing a post-launch fourth phase study. Hyderabad-based Natco Pharma has presented the proposal for the grant of permission to manufacture and market erdafitinib in three different strengths along with the 'justification" for a waiver on local third-phase clinical trials, as per the minutes of the meeting of the technical committee dated July 17. 'After detailed deliberation, the committee opined that there is an unmet medical need for the proposed indication in the country," said the minutes, which were accessed by News18. 'The committee recommended for the grant of permission to manufacture and market the drug Erdafitinib Tablet 3 mg, 4 mg and 5 mg with local Phase III clinical trial waiver." This marks a significant shift from the 2023 stance, when the subject expert committee (SEC), functioning under Central Drugs Standard Control Organisation (CDSCO), had rejected Natco's request for a Phase-III waiver. After reviewing the bioequivalence data, the SEC asked the company to 'submit the Phase-III clinical trial protocol before the committee for further consideration". That earlier decision underscored the caution about approving cancer treatments without robust local safety and efficacy data. According to the GLOBOCAN 2020 database, bladder cancer is the 17th most common malignancy in India. The five-year prevalence appears to be 3.57 per 1,00,000 population, leading to about 11,000 deaths each year. The incidence of bladder cancer is higher in males as compared to females. Data shows that bladder cancer incidence does vary across India. Among males, Delhi had the highest incidence rates followed by Thiruvananthapuram and Kolkata, and the lowest rate was in Dibrugarh. When it comes to females, the rate is highest in Delhi followed by Mumbai and Mizoram, respectively, and lowest in Barshi. Over time, bladder cancer incidence has increased in Delhi, Bengaluru and Mumbai, while it has decreased in Chennai. WHAT MAKES ERDAFITINIB IMPORTANT? Erdafitinib is a targeted therapy that inhibits the fibroblast growth factor receptor (FGFR) – a key driver of rapid tumour growth in certain bladder cancers. The FGFR gene gives the body instructions to make FGFR proteins, which sit on the surface of cells. These proteins receive growth signals (called fibroblast growth factors) and tell the cell when to grow, divide, or repair itself. On January 19, 2024, the US FDA approved erdafitinib, sold under the brand name Balversa, developed by Janssen Biotech, a Johnson & Johnson company. The drug has been approved for adults with advanced or metastatic bladder cancer that has certain FGFR3 gene changes, confirmed by an approved test. It can be used if the cancer has worsened after at least one previous systemic treatment. It is not meant for patients who could still benefit from PD-1 or PD-L1 immunotherapy and have not yet tried it. ONCOLOGISTS WELCOME THE MOVE According to the sellers on the online platform Indiamart, the bottle containing 56 tablets of 4mg Erdafitinib is sold at Rs 7,000, which is Rs 125 per tablet. With local manufacturing, however, the cost is expected to drop by more than 50 per cent. 'It's a good drug for bladder cancer patients with locally advanced disease not responding to chemotherapy. This is targeted therapy that blocks fibroblast growth factor receptor (FGFR). This fibroblast growth factor helps cancer grow fast. This medicine blocks this growth and helps control cancer," said Dr Satya Prakash Yadav, director of paediatric haematology-oncology and bone marrow transplant at Medanta Hospital. Similarly, Dr Pragya Shukla, who leads the clinical oncology department at Delhi State Cancer Institute, said the drug is for FGFR-altered metastatic urothelium, which has failed on multiple lines of chemotherapy and has shown benefits in overall survival in this particular group of patients. As the panel cited 'unmet demand", Dr Shukla said: 'The drug should definitely benefit a particular group of patients waiting for a targeted therapy." WHAT COMES NEXT? If the technical committee's recommendation is adopted into a final CDSCO order, Natco Pharma may roll out erdafitinib across India – provided it submits a robust Phase-IV study protocol within three months of approval. A fourth phase trial is the stage of research that happens after a drug has been approved by regulators and is already being sold in the market. It is also called post-marketing surveillance or post-approval study. It can reveal safety issues, interactions, or benefits that did not appear in smaller or shorter trials before, and at times lead to changes in how the drug is prescribed – or even withdrawal if serious risks are found.
Hindustan Times
2 hours ago
- Hindustan Times
Govt issues note on birth, death registration
Dr Babita Kamlapurkar, deputy director, health services issued a note on Monday on mandatory registration of births and deaths. For births or deaths at home, the head of the family is responsible for reporting them, officials said, adding that birth registration can be done without a name, which can be added later. (REPRESENTATIVE PHOTO) 'The first copy of a birth or death certificate is issued free of cost and additional copies can be obtained on payment. Corrections are allowed under certain conditions, and foreign births can be registered at Indian embassies abroad and later in India, though foreign deaths cannot be registered here,' she said. The Registration of Births and Deaths Act, 1969, implemented by the central government, governs the registration process. For births or deaths at home, the head of the family is responsible for reporting them, officials said, adding that birth registration can be done without a name, which can be added later. Delay in registration of birth and death by one year needs a magistrate's order and requisite fee.
Hindustan Times
4 hours ago
- Hindustan Times
Pune zoo records India's first wild animal case of deadly MCF virus
The genome of the Malignant Catarrhal Fever (MCF) virus, which records high fatality rates, was detected in a wild animal at the Rajiv Gandhi Zoological Park, Pune, in a first for India. The finding was confirmed by the ICAR–National Institute of High Security Animal Diseases (NIHSAD), Bhopal, on July 29, following tests on specimens sent by the Western Regional Disease Diagnostic Laboratory (WRDDL), Pune. While harmless to humans, MCF poses a major threat to wildlife conservation and livestock health. In an August 5 communication, the ministry termed the detection 'a serious concern' as MCF had never before been reported in a wild animal in India. (HT FILE) Between July 6 and 12 this year, 16 spotted deer at the zoo died in a highly contagious viral outbreak. Samples from the dead animals were sent to multiple laboratories for diagnosis. On July 24, reports from the ICAR–National Institute on Foot and Mouth Disease (Bhubaneswar) and NIHSAD (Bhopal) confirmed foot and mouth disease. However, a separate NIHSAD report on July 29 confirmed the presence of the MCF genome in one of the samples. Following this, the Union Ministry of Fisheries, Animal Husbandry & Dairying issued an advisory to state authorities. In an August 5 communication, the ministry termed the detection 'a serious concern' as MCF had never before been reported in a wild animal in India. Caused primarily by Ovine Herpesvirus-2 (OvHV-2), the disease affects wild and domestic ruminants, with sheep and goats serving as symptomless carriers. There is currently no effective treatment or vaccine. The ministry directed Maharashtra's forest and animal husbandry departments to immediately enforce strict biosecurity and movement control measures in and around the zoo, enhance surveillance of susceptible species such as deer, bison, and antelopes, and ensure regular health monitoring with prompt reporting of unusual animal deaths. On August 6, Maharashtra Animal Husbandry Commissioner Dr. Pravinkumar Deore instructed district animal husbandry and forest officials to act swiftly to prevent further spread. His letter reiterated that MCF is a highly fatal disease not previously reported in India and stressed early detection, biosecurity, and inter-agency coordination. Officials were told to remain alert and report any unusual mortalities to the District Deputy Commissioner, Animal Husbandry and Dairying. However, Rajkumar Jadhav, Director of Rajiv Gandhi Zoological Park, denied that the zoo's animals were affected. 'This illness is generally found in cattle and livestock, and the claim that it has been identified here for the first time is not correct. Since the last reported death, we have implemented all necessary safety measures and vaccinations. The animals are now in healthy condition,' he said. A wildlife expert, requesting anonymity, called the detection 'a serious concern' given the absence of prior records of MCF in Indian wildlife. 'It is a fatal disease, and death can occur within one to three days without timely intervention. Preventive measures are often neglected, but in zoos and rescue centres, keepers and handlers must strictly follow biosafety protocols as they can be carriers of the virus directly or indirectly,' the expert said. What is MCF? Malignant Catarrhal Fever is a rare but deadly viral disease affecting cattle, bison, deer, and other ruminants. It is caused by viruses carried harmlessly by sheep and wildebeest. Transmission occurs through nasal and eye secretions from carriers, but the disease does not infect humans. Symptoms in affected animals include high fever, nasal and eye discharge, mouth sores, and rapid deterioration leading to death. There is no cure; prevention relies on separating carriers from susceptible species. Safety advisory highlights *Enforce strict biosecurity and movement control measures in and around the zoo. *Intensify surveillance of susceptible species such as deer, bison, and antelopes, and submit samples to ICAR–NIHSAD *Conduct regular health monitoring of wild animals and strengthen early warning systems.
